In conclusion, plasmatic levels of HSP90α at diagnosis can be considered a potential independent prognostic marker of advanced lung cancer patients treated with PD-1/PD-L1 inhibitors plus chemotherapy. The gene discussed is PDCD1; the disease is lung carcinoma.